Literature DB >> 3972444

Role of fibronectin in human monocyte and macrophage bactericidal activity.

R A Proctor, J A Textor, J M Vann, D F Mosher.   

Abstract

Fibronectin is a high-molecular-weight glycoprotein found as a soluble dimer in plasma and as an insoluble multimer in tissues. It has been proposed that plasma fibronectin facilitates phagocytic removal of lysed cells and damaged tissues. Fibronectin binds avidly to several species of gram-positive bacteria and enhances staphylococcal and streptococcal attachment to cultured cells. Determination of whether fibronectin will enhance the bactericidal activity of monocytes and macrophages has not been reported. The bactericidal activity of freshly isolated monocytes, cultured monocytes, or lymphokine-activated macrophages was tested in the presence of either dimeric or multimeric fibronectin. Freshly isolated monocytes and lymphokine-activated macrophages killed Staphylococcus aureus effectively in the absence of fibronectin or whole serum. In contrast, monocytes cultured for 7 to 10 days had diminished staphylocidal capacity. When the monocytes were cultured with either dimeric or multimeric fibronectin, however, bactericidal capacity was maintained. Thus, although fibronectin did not enhance the bactericidal activity of mononuclear phagocytes, both multimeric and dimeric fibronectin were effective at maintaining the bactericidal capacity.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3972444      PMCID: PMC261340          DOI: 10.1128/iai.47.3.629-637.1985

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  62 in total

1.  Purification of opsonically active human and rat cold-insoluble globulin (plasma fibronectin).

Authors:  J Molnar; F B Gelder; M Z Lai; G E Siefring; R B Credo; L Lorand
Journal:  Biochemistry       Date:  1979-09-04       Impact factor: 3.162

2.  Scanning electron microscopy of the attachment of human polymorphonuclear leukocytes to staphylococcus aureus.

Authors:  A S Klainer; C J Betsch
Journal:  J Infect Dis       Date:  1973-06       Impact factor: 5.226

3.  Purification and characterization of a protein with fibronectin determinants and phagocytosis-enhancing activity.

Authors:  J K Czop; J L Kadish; K F Austen
Journal:  J Immunol       Date:  1982-07       Impact factor: 5.422

4.  Augmentation of phagocytosis by a specific fibronectin fragment that links particulate activators to the fibronectin adherence receptor of human monocytes.

Authors:  J K Czop; K F Austen
Journal:  J Immunol       Date:  1982-12       Impact factor: 5.422

5.  Fibronectin enhances in vitro monocyte-macrophage-mediated tumoricidal activity.

Authors:  R T Perri; N E Kay; J McCarthy; R L Vessella; H S Jacob; L T Furcht
Journal:  Blood       Date:  1982-08       Impact factor: 22.113

6.  Depression of phagocytosis by plasmin degradation products of plasma fibronectin.

Authors:  M I Ehrlich; J S Krushell; F A Blumenstock; J E Kaplan
Journal:  J Lab Clin Med       Date:  1981-08

7.  Interaction of human plasma fibronectin with cariogenic and non-cariogenic oral streptococci.

Authors:  J P Babu; W A Simpson; H S Courtney; E H Beachey
Journal:  Infect Immun       Date:  1983-07       Impact factor: 3.441

8.  Reversible binding of a guinea-pig lymphokine to gelatin and fibrinogen: possible relationship of macrophage agglutination factor and fibronectin.

Authors:  H P Godfrey; A Purohit
Journal:  Immunology       Date:  1982-07       Impact factor: 7.397

9.  Plasma fibronectin enhances phagocytosis of opsonized particles by human peripheral blood monocytes.

Authors:  C G Pommier; S Inada; L F Fries; T Takahashi; M M Frank; E J Brown
Journal:  J Exp Med       Date:  1983-06-01       Impact factor: 14.307

10.  Fibronectin-mediated uptake of gelatin-coated latex particles by peritoneal macrophages.

Authors:  P W Gudewicz; J Molnar; M Z Lai; D W Beezhold; G E Siefring; R B Credo; L Lorand
Journal:  J Cell Biol       Date:  1980-11       Impact factor: 10.539

View more
  9 in total

1.  Plasma fibronectin concentrations in patients with human immunodeficiency virus infection.

Authors:  D Torre; M Issi; C Sampietro; G P Fiori; G Chelazzi; G Ferraro
Journal:  J Clin Pathol       Date:  1990-07       Impact factor: 3.411

2.  Fibronectin as an enhancer of nonopsonic phagocytosis of Pseudomonas aeruginosa by macrophages.

Authors:  J L Kluftinger; N M Kelly; B H Jost; R E Hancock
Journal:  Infect Immun       Date:  1989-09       Impact factor: 3.441

3.  Localization of fibronectin in human middle ear cholesteatoma.

Authors:  W Y Chao; Q G Yuan; C C Huang
Journal:  Arch Otorhinolaryngol       Date:  1988

4.  Growth inhibition of Cryptococcus neoformans by cultured human monocytes: role of the capsule, opsonins, the culture surface, and cytokines.

Authors:  S M Levitz; T P Farrell
Journal:  Infect Immun       Date:  1990-05       Impact factor: 3.441

5.  Antibody-independent interactions of fibronectin, C1q, and human neutrophils with Treponema pallidum.

Authors:  R E Baughn
Journal:  Infect Immun       Date:  1986-11       Impact factor: 3.441

6.  Mechanisms of nonopsonic phagocytosis of Pseudomonas aeruginosa.

Authors:  T Mork; R E Hancock
Journal:  Infect Immun       Date:  1993-08       Impact factor: 3.441

7.  Cerebrospinal fluid concentration of fibronectin in patients with HIV-1 infection and central nervous system disorders.

Authors:  D Torre; C Zeroli; G Ferrario; G Bonetta; G P Fiori; R Martegani
Journal:  J Clin Pathol       Date:  1993-11       Impact factor: 3.411

8.  Effect of milk on fibronectin and collagen type I binding to Staphylococcus aureus and coagulase-negative staphylococci isolated from bovine mastitis.

Authors:  J Miedzobrodzki; A S Naidu; J L Watts; P Ciborowski; K Palm; T Wadström
Journal:  J Clin Microbiol       Date:  1989-03       Impact factor: 5.948

9.  Stimulation by fibronectin of macrophage-mediated phagocytosis of Pseudomonas aeruginosa.

Authors:  J L Kluftinger; N M Kelly; R E Hancock
Journal:  Infect Immun       Date:  1989-03       Impact factor: 3.441

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.